The randomized phase II AVANOVA trial compared niraparib plus the Vascular Endothelial Growth Factor-A (VEGF-A) inhibitor bevacizumab to niraparib alone in platinum-sensitive recurrent ovarian cancer patients [88]. The gene discussed is VEGFA; the disease is ovarian cancer.